Investigation of the Analgesic Properties L-759,633 and SER 601 in Experimental Neuropathic Pain Model in Rats and their Comparison with Pregabalin

Zıad Joha; Şahin Yıldırım; Levent Hacısüleyman; Ahmet Şevki Taşkıran

doi:10.17776/csj.1060972

Research Article

Investigation of the Analgesic Properties L-759,633 and SER 601 in Experimental Neuropathic Pain Model in Rats and their Comparison with Pregabalin

Year 2023, , 41 - 45, 26.03.2023

Zıad Joha , Şahin Yıldırım , Levent Hacısüleyman Ahmet Şevki Taşkıran

https://doi.org/10.17776/csj.1060972

Abstract

Despite the fact that narcotics and NSAIDs are the mainstays of nociceptive pain care, only a small proportion of neuropathic pain patients benefit from them. Cannabinoid agents could be a viable alternative to opioids in the management of chronic pain. The goal of our investigation was to assess the analgesic efficacy of SER 601 and L-759,633, cannabinoid receptor 2 (CB2) agonists, at various doses in a model of neuropathic pain generated in rat. The analgesic effect of CB2 agonists L-759,633 and SER 601 at various doses in a rat model of neuropathic pain created by partial sciatic nerve ligation was examined by the hot plate method. Furthermore, a comparison of analgesic effects of both drugs with pregabalin is also conducted. The two substances demonstrated a dose-dependent analgesic effect in this model. The analgesic response of SER601 and L-759,633 in the neuropathic pain model was higher compared to that of pregabalin. All in all, our data suggest that SER601 and L-759,633 may offer a beneficial treatment option for neuropathic pain in future.

Keywords

Neuropathic pain, L-759, 633, SER 601, Hot plate, Pregabalin.

Supporting Institution

cumhuriyet university scientific research project

Project Number

T-848

References

[1] Mills S. E., Nicolson K. P., Smith B. H., Chronic pain: a review of its epidemiology and associated factors in population-based studies, British Journal of Anaesthesia, 123(2) (2019) 273-283.
[2] Ricci L., Luigetti M., Florio L., Capone F., Di Lazzaro V., Causes of chronic neuropathies: a single-center experience, Neurological Sciences, 40(8) (2019) 611-1617.
[3] Koetsier E., Franken G., Debets J., Heijmans L., van Kuijk S. M., Linderoth B., Maino P., Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord, CNS Neuroscience & Therapeutics, 26(1) (2020) 136-143.
[4] Devor M., Neuropathic pain and injured nerve: Peripheral mechanisms, Br. Med. Bull., 47 (1991) 619–30.
[5] Cohen S.P., Mao J., Neuropathic pain: Mechanisms and their clinical implications, BMJ, 348 2014.
[6] Henningsen P., Zipfel S., Herzog W., Management of functional somatic syndromes, Lancet, 369 (2007) 946–55.
[7] Dworkin R.H., O’Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Pharmacologic management of neuropathic pain: Evidence-based recommendations, Pain, 132 (2007) 237–51.
[8] Lötsch J., Weyer-Menkhoff I., Tegeder I., Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings, Eur. J. Pain, 22 (2018) 471–84.
[9] Ibrahim M.M., Deng H., Zvonok A., Cockayne D.A., Kwan J., Mata H.P., Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS, Proc. Natl. Acad. Sci., 100 (2003) 10529–33.
[10] Meymandi M. S., Sepehri G., Abdolsamadi M., Shaabani M., Heravi G., Yazdanpanah O., Aghtaei M. M., The effects of co-administration of pregabalin and vitamin E on neuropathic pain induced by partial sciatic nerve ligation in male rats, Inflammopharmacology, 25(2) (2017) 237-246.
[11] Kanaan S.A., Saadé N.E., Haddad J.J., Abdelnoor A.M., Atweh S.F., Jabbur S.J., Endotoxin-induced local inflammation and hyperalgesia in rats and mice: A new model for inflammatory pain, Pain, 66 (1996) 373–379.
[12] Malmberg A.B., Basbaum A.I., Partial sciatic nerve injury in the mouse as a model of neuropathic pain: Behavioral and neuroanatomical correlates, Pain, 76 (1998) 215–222.
[13] Seltzer Z., Dubner R., Shir Y., A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury, Pain, 43 (1990) 205–18.
[14] Altun A., Yildirim K., Ozdemir E., Bagcivan I., Gursoy S., Durmus N., Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists, J. Physiol. Sci., 65 (2015) 407–15.
[15] Kirsh K.L., Passik S.D., Rich B.A., Failure to Treat Pain. Treat. Chronic Pain by Integr. Approaches, Springer New York; (2015) 307–312.
[16] Guindon J., Hohmann A.G., Cannabinoid CB 2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain, Br. J. Pharmacol., 153 (2008) 319–34.
[17] Hossain M.Z., Ando H., Unno S., Kitagawa J., Targeting peripherally restricted cannabinoid receptor 1, cannabinoid receptor 2, and endocannabinoid-degrading enzymes for the treatment of neuropathic pain including neuropathic orofacial pain, Int. J. Mol. Sci., (2020) 21-28.
[18] Craft R.M., Greene N.Z., Wakley A.A., Antinociceptive effects of JWH015 in female and male rats, Behav Pharmacol., 29 (2018) 280–289.
[19] Lynch M.E., Ware M.A., Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials, J. Neuroimmune Pharmacol., 10 (2015) 293–301.
[20] Yekkirala A.S., Roberson D.P., Bean B.P., Woolf C.J., Breaking barriers to novel analgesic drug development, Nat. Rev. Drug Discov., 16 (2017) 545–64.
[21] Li A.L., Lin X., Dhopeshwarkar A.S., Thomaz A.C., Carey L.M., Liu Y., Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal, Mol. Pharmacol., 95 (2019) 155–68.
[22] Sheng W.S., Chauhan P., Hu S., Prasad S., Lokensgard J.R., Antiallodynic effects of cannabinoid receptor 2 (CB2R) agonists on retrovirus infection-induced neuropathic pain, Pain Res. Manag., (2019) 245-254
[23] Li A.L., Carey L.M., Mackie K., Hohmann A.G., Cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice, J. Pharmacol. Exp. Ther., 362 (2017) 296–305.
[24] Pasquini S., Botta L., Semeraro T., Mugnaini C., Ligresti A., Palazzo E., Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo, J. Med. Chem., 2008 (51) 5075–84.
[25] Contartese A., Valoti M., Corelli F., Pasquini S., Mugnaini C., Pessina F., A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury, Pharmacol. Res., 2012 (66) 555–563.
[26] Starowicz K., Finn D.P., Cannabinoids and Pain: Sites and Mechanisms of Action, Adv., Pharmacol., 80 (2017) 437–75.
[27] Strangman N.M., Walker J.M., Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses, J. Neurophysiol., 1999 (82) 472–477.
[28] Ibrahim M.M., Porreca F., Lai J., Albrecht P.J., Rice F.L., Khodorova A., CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids, Proc. Natl. Acad. Sci. 2005 102 3093–3098.